Biotech Values

[DewDiligence]

2Q17 worldwide Botox sales=$816M, +13% YoY (+14% QoQ*):

https://finance.yahoo.com/news/allergan-reports-continued-strong-execution-115100875.html

• US therapeutic: $346.9M (+17% YoY)
• US cosmetic: $227.1M (+20% YoY)
• Ex-US therapeutic: $93.8M (+14% YoY in local currency)
• Ex-US cosmetic: $148.3M (+12% YoY in local currency)

In other words, 70% of Botox sales were in the US, where the therapeutic/cosmetic split was 60/40; 30% of Botox sales were ex-US, where the therapeutic/cosmetic split was 39/61.

*The large 2Q17-vs-1Q17 growth was expected; for cosmetic indications, the second and fourth quarters are seasonally stronger than the first and third quarters.